Valuation: Save Foods Inc

Market Cap 851K 762K 701K 635K 1.19M 80.77M 1.21M 8.36M 3.35M 42.49M 3.19M 3.12M 134M P/E 2024
-0.28x
P/E 2025 -0.34x
Enterprise Value -2.23M -2M -1.84M -1.66M -3.11M -212M -3.17M -21.89M -8.79M -111M -8.36M -8.19M -351M EV / Sales 2024
1.64x
EV / Sales 2025 -
Free-Float
87.05%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 60 2020-11-04
Director of Finance/CFO 39 2022-04-17
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 54 2020-08-25
Chairman 62 2021-05-23
Director/Board Member 54 2020-08-25
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%-0.69%+27.56%+25.16% 33.16B
+4.41%+2.17%+48.90%+51.79% 18.66B
+0.37%-2.25%-13.45%+29.39% 17.29B
-0.52%+5.02%-6.20%-10.71% 14.59B
+0.11%-.--%-.--%-.--% 12.96B
+0.31%-2.23%+7.27%+8.07% 10.91B
0.00%-4.29%-1.12%+145.70% 9.45B
-0.22%-.--%-.--%-.--% 8.3B
+1.48%-6.51% - - 7.77B
Average +0.80%+0.15%+7.87%+31.17% 14.79B
Weighted average by Cap. +1.03%+0.27%+12.54%+28.87%

Financials

2024 2025
Net sales 210K 188K 173K 157K 293K 19.94M 298K 2.06M 828K 10.49M 788K 771K 33.08M -
Net income -5.19M -4.65M -4.28M -3.88M -7.25M -493M -7.38M -51.02M -20.48M -259M -19.49M -19.07M -818M -4M -3.59M -3.3M -2.99M -5.59M -380M -5.69M -39.34M -15.79M -200M -15.03M -14.71M -631M
Net Debt -2.48M -2.23M -2.05M -1.85M -3.47M -236M -3.53M -24.41M -9.8M -124M -9.33M -9.13M -391M -3.08M -2.76M -2.54M -2.3M -4.3M -292M -4.38M -30.25M -12.14M -154M -11.56M -11.31M -485M
Logo Save Foods Inc
Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.
Employees
-